G1 Therapeutics, Inc. - GTHX STOCK NEWS

G1 Therapeutics (GTHX) announced initial results from a Phase 2 trial of trilaciclib in early-stage triple-negative breast cancer (TNBC), demonstrating favorable changes in the tumor microenvironment. The trial showed an increased ratio of CD8+ T cells to T regulatory cells post-treatment in 23 evaluable patients. Results were presented at the San Antonio Breast Cancer Symposium. The company anticipates further insights into trilaciclib's effectiveness in enhancing anti-tumor responses in conjunction with chemotherapy and checkpoint inhibitors, with full results expected in Q2 2023.

G1 Therapeutics, Inc. (GTHX) announced on December 1, 2022, the grant of stock options for 14,400 shares and 9,400 restricted stock units (RSUs) to five new employees under its Amended and Restated 2021 Plan. These equity awards are part of the company's strategy to attract talent and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $5.85 per share and a ten-year term, vesting over four years. RSUs will vest over four years as well, starting with 25% on the first anniversary.

On November 30, 2022, at 1:25 PM EST, G1 Therapeutics (GTHX) will participate in the Evercore ISI HealthCONx Conference via a virtual fireside chat featuring CEO Jack Bailey and the executive team. This event will focus on G1's commitment to developing and commercializing innovative therapies for cancer patients, including their first product, COSELA® (trilaciclib). Interested parties can access the live webcast and replay on G1's Events & Presentations page.

G1 Therapeutics announced the closing of an underwritten public offering of 7,700,000 shares of its common stock priced at $6.50 per share. The company received $50,050,000 in gross proceeds from the offering, before expenses. An option is available for underwriters to purchase an additional 1,155,000 shares. The offering was made under a previously filed effective registration statement with the SEC. G1 is focused on developing therapies for cancer, including its product COSELA® (trilaciclib).

G1 Therapeutics, Inc. (Nasdaq: GTHX) has priced an underwritten public offering of 7,700,000 shares of common stock at $6.50 each, totaling gross proceeds of $50,050,000. All shares will be sold by G1 Therapeutics, with a 30-day option for underwriters to purchase an additional 1,155,000 shares. The offering is set to close on November 22, 2022. Joint book-running managers include Cowen and Raymond James, while Needham & Company and Wedbush PacGrow serve as lead managers. This offering is conducted under a previously filed shelf registration with the SEC.

G1 Therapeutics, Inc. (Nasdaq: GTHX) has announced an underwritten public offering of its common stock, with all shares offered by the company. The offering includes a 30-day option for underwriters to purchase up to an additional 15% of the offered shares. Cowen and Raymond James & Associates are the joint book-running managers. This offering is subject to market conditions, and the shares are offered under a previously filed shelf registration statement with the SEC. A preliminary prospectus will be available through the SEC's website.

G1 Therapeutics reported total revenues of $23.6 million for Q3 2022, including $8.3 million from COSELA sales. The company completed patient enrollment in pivotal Phase 3 trials for metastatic triple-negative breast cancer and Phase 2 trials for bladder cancer. Recent Phase 2 data suggest trilaciclib could significantly reduce adverse events related to antibody-drug conjugates. However, G1's CEO acknowledged lower sales momentum for COSELA compared to Q2, prompting a focus on boosting market presence. Cash reserves stood at $123 million at the quarter's end.

G1 Therapeutics has released preliminary safety data from its ongoing Phase 2 study of trilaciclib in combination with sacituzumab govitecan-hziy for patients with metastatic triple-negative breast cancer (TNBC). The initial findings from 18 patients indicate that administering trilaciclib may significantly reduce adverse events, particularly myelosuppression, diarrhea, and potentially alopecia. The company anticipates presenting more comprehensive data, including initial efficacy results, at a medical meeting in Q2 2023.

G1 Therapeutics, Inc. (GTHX) announced the grant of stock options for 5,200 shares and 3,400 restricted stock units (RSUs) to a newly hired employee under its Amended and Restated 2021 Inducement Equity Incentive Plan. The stock options are exercisable at $10.91 per share, have a ten-year term, and vest over four years. The RSUs also vest over a four-year period. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are aimed at attracting talent as part of G1’s strategy to enhance its workforce.